Objective To conduct a systematic review of cost-effectiveness, cost-utility, and cost-benefit studies of DPP-4 inhibitors for diabetes treatment versus other antidiabetics. Methods Three investigators searched the CRD York, Tufts CEA Registry, and MEDLINE databases through 2015. We reviewed all potentially relevant titles and abstracts, and screened full-text articles, according to inclusion criteria. We established a quality score for each study based on a 35-item list. Results A total of 295 studies were identified, of which 20 were included. The average quality score was 0.720 on a 0-1 scale. All studies were performed in high-and middleincome countries, using a 3rd-party payer perspective and randomized clinical trials to measure effectiveness. Sitagliptin, saxagliptin and vildagliptin had an ICER below 25,000 €/QALY, as second-line and as add-ons to metformin, in comparison to sulfonylureas. When compared with sitagliptin, liraglutide (GLP-1 receptor agonist) had an ICER of up to 22,724 €/QALY for the 1.2-mg dosage, and up to 32,869 €/QALY for the 1.8-mg dosage. Insulin glargine was dominant when compared with sitagliptin. Conclusions According to the WHO threshold applied to the country and year of each study, DPP-4 inhibitors were highly cost-effective as second-line, as add-ons to metformin, in comparison with sulfonylureas. More recent therapies (GLP-1 receptor agonists and insulin glargine) were highly cost-effective in comparison to DPP-4 inhibitors. These results were obtained, however, on the basis of a limited number of studies, relying on the same few clinical trials, and financed by manufacturers. Further independent research is needed to confirm these findings.
Introduction
Diabetes is one of the largest global health emergencies of the twenty-first century. In addition to the 415 million adults estimated to have diabetes in 2015, there are 318 million adults with impaired glucose tolerance, which puts them at high risk of developing the disease in the future [1] . Also, according to the International Diabetes Federation (IDF), 5 million people died of diabetes in 2015. Upper middle-income and high-income countries are those where the prevalence of diabetes is highest amongst those 20-79 years old [1] .
Regarding the economic burden, the majority of high-income countries spend between 5 and 20 % of their total health expenditure on diabetes [1] . In France total direct costs reached 12.9 € billion in 2010. In Germany the total direct cost burden arising from treatment has been estimated at 43.2 € billion for 2010. Total direct cost in the UK has been estimated at £13.8 billion (20.2 € billion using the base year rate of exchange) [2] . In 2012 the total estimated cost of diagnosed diabetes in the United States was $245 billion, including $176 billion in direct medical costs and $68 billion in indirect costs [3] . These indirect costs included increased absenteeism ($5 billion) and reduced productivity while at work ($20.8 billion) for the employed population, reduced productivity for those not in the labour force ($2.7 billion), inability to work as a result of disease-related disability ($21.6 billion), and lost productive capacity due to early mortality ($18.5 billion). On average, medical expenditures among people with diabetes are approximately 2.3 times higher than among those without diabetes [3] .
As a result, diabetes has been considered to be a research priority, leading to a large increase in recent years in the number of glucose lowering medicines for treating type 2 diabetes. Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are a relatively new oral hypoglycaemic drugs group. Among these, sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin are currently approved by the US Food and Drug Administration and the European Medicines Agency, while others are awaiting approval or are in development. In practice, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) clinical guideline for type 2 diabetes, suggested adding a DPP-4 inhibitor, insulin, glucagon-like peptide 1 (GLP-1) receptor agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinedione, or a sulfonylurea as secondline treatment to first-line metformin [4] .
Drug choice is based on patient preferences as well as various patient, disease, and drug characteristics, with the goal being to reduce glucose concentrations while minimizing side effects, especially hypoglycemia [4] . However, the guideline did not incorporate cost-effectiveness considerations regarding the newest medicines, such as DPP-4 inhibitors or SGLT2 inhibitors, which are nevertheless essential as an instrument to help resource allocation decisions. The importance is also emphasized in the current context of economic recession and pressure on tight public budgets, and considering the high epidemiological and economic burden of the disease.
The objective of this study was to conduct a systematic review of cost-effectiveness, cost-utility, and cost-benefit studies of DPP-4 inhibitors versus other antidiabetics as treatment of type 2 diabetes mellitus (T2DM), and understand the implications for guidelines, policy, and further research.
Methods
This review followed the methodology recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [5] , and by the Centre for Reviews and Dissemination (CRD) of the University of York for systematic reviews of economic evaluations [6] .
The literature review was based on a search for journal articles and abstracts in Medline and the CRD database from 1996 to 2015, and NHS EED, the Health Economic and Evaluations Database (HEED), and the Tufts CEA Registry to 2015. Google scholar was also searched. In addition, relevant grey literature, including models presented at recent professional meetings available solely as abstracts in conference proceedings, were also explored.
Searches for economic outcomes were conducted using a variety of terms from the medical literature to describe the intervention, the comparator, the target patient population, the outcomes, and the study design. A combination of these search terms was also used for the survey. The search terms were: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, DPP-4 inhibitors, cost-effectiveness, cost-utility, and cost-benefit. The search strings used for the PubMed searches are available in the Appendix.
Firstly, three investigators independently reviewed all potentially relevant titles and abstracts (1st screening) and subsequently screened full-text articles (2nd screening), according to pre-established inclusion criteria. Inclusion criteria followed the PICOS approach [7] . PICOS is the acronym for population, intervention, comparator, outcomes, and study design. We followed the PRISMA flowchart in reporting study selection, as suggested by the PRISMA statement [5] .
Cost-effectiveness, cost-utility studies, and cost-benefit studies should be available as a full-text publication and published in English, French, Spanish, or Portuguese languages. We excluded the incomplete economic evaluations, namely: cost consequence analyses (4 studies); patient reported outcomes (PRO) studies (1 study); the studies on sub-populations that cannot be generalized (2 studies); the health technology assessment agencies reports that were not submitted to peer-review (36 studies); studies out of scope (162), and only abstracts (66).
Secondly, the three investigators used a standardized data abstraction template, as recommended by the CRD of the University of York for systematic reviews of economic evaluations [6] , to independently extract data from each study, with disagreements being resolved by discussion. For each study, the information was extracted and recorded in a specific template, provided in the Appendix.
Thirdly, a critical appraisal of the methodology and reporting was performed focusing on key quality issues, such as: methods of deriving the effectiveness data; measurement and valuation of resource data; measurement and valuation of health benefits (utilities); method of synthesizing the costs and effects; analysis of uncertainty; and external validity. To do so, we used the 35-item version of the BMJ checklist [7] . A score in percentage was attributed to each study, calculating the affirmative answers in the checklist. Three investigators performed all quality assessments independently, with disagreement resolved through discussion.
Finally, we reported summary statistics and qualitative (descriptive) syntheses of identified cost-effectiveness, cost-utility, and cost-benefit studies in the form of summary tables. Categorical data were reported as percentages, while continuous data were reported as means with confidence intervals or standard deviations. A comparative qualitative synthesis was performed to explore relationships within and between studies.
Results
The literature search initially identified 295 citations (Fig. 1 ). Of these, 24 cost-effectiveness studies were accepted after the 1st screening, and 20 were accepted after the 2nd screening.
Characteristics of the selected publications
Main details of the selected studies are presented in Table 1 . We organized these results according to the timing of the market introduction, that is: (1) sitagliptin versus sulfonylurea; (2) saxagliptin versus sulfonylurea; (3) saxagliptin versus insulin; (4) saxagliptin versus pioglitazone; (5) vildagliptin versus sulfonylurea; (6) liraglutide versus sitagliptin; (7) insulin glargine versus sitagliptin; and (8) GLP-1 receptor agonists versus DPP-4 inhibitors.
The studies were all performed in high-income and middle-income countries (using the World Bank classification) [8] . The high-income countries were Austria, Canada, Finland, Germany, Greece, Poland, Portugal, Spain, Sweden, United Kingdom (UK), and United States (US). The middle-income countries were Argentina and Brazil. These are very recent studies with retrieval of data: one study from 2014, four studies from 2013, five studies from 2012, two studies from 2011, one study from 2010, four studies from 2009, two studies from 2008, and one Studies included in the review n= 20
Relevant titles and abstracts identified n= 303
Flowchart of the literature search The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 939 study from 2007. There were four studies with a societal perspective and sixteen studies with a 3rd-party payer perspective. The societal perspective is the broadest and most complex perspective, in which ideally the estimated costs reflect the true social opportunity costs, while the 3rd-party payer perspective reflects only the costs borne by that payer. Costs measurements should be fully transparent and the perspective adopted defines the scope of the analysis, with different countries having different guidelines for this issue [9] . One single study used an observational study providing real-world effectiveness data. The majority of the studies were based on one randomized controlled trial. Sitagliptin was assessed in eleven studies, saxagliptin in seven studies, vildagliptin in one study, and the three DPP-4 inhibitors (sitagliptin, saxagliptin, and vildagliptin) were also assessed jointly versus two GLP-1 receptor agonists (liraglutide and exenatide) in one study.
All but one study evaluated these drugs as add-on to metformin monotherapy as second-line, that is, for those patients who did not achieve glycaemic control with metformin as first-line. One study did not specify clearly whether the drug was assessed as second-line. Finally, the majority of studies included in this review were of high quality (average score 0.720 on a 0-1 scale, with a range between 0.485 and 0.885).
The World Health Organization (WHO) threshold for cost-effectiveness was used as Ref. [10] . This criterion defined a strategy as cost-effective when the cost per DALY averted or QALY gained was less than 3 times the gross domestic product (GDP) per capita, and as very costeffective if it was less than the GDP per capita [11] . The threshold was calculated for each study on the basis of the year and country where the study was performed.
Main results of the selected publications
These findings are reported in Table 2 , according to the timing of the market introduction mentioned in the Methods section. More complete details of the studies, including the characteristics of the base population, are shown in Table A .1, in the Appendix.
First, we compared sitagliptin with sulfonylureas [12, 13] . The studies used the Januvia Diabetes Economic model (JADE). The JADE model is a discrete event simulation model developed to project the long-term impacts of different interventions on diabetes related outcomes [32] . It is an extension of the more well-known United Kingdom Prospective Diabetes Study (UKPDS) outcomes model, to which it adds the possibility of modelling the effect of different treatment regimes in terms of health outcomes, costs, and quality of life. The UKPDS appears as less complete than the IMS core model-the most well- The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 943 Exchange rates were assessed on 15 May 2015 using the converting tool of the Portuguese National Bank (https://www.bportugal.pt/en-US/Estatisticas/Dominios%20Estatisticos/Estatisti casCambiais/Pages/Taxasdereferenciadiarias.aspx)
The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 947 The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 949 The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 951 The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 953 The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 955 The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 957 The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 959 known and widely used model, presented below-because it includes fewer complications and does not encompass the interactions between them, and also because the disease progression is modelled in a limited way for some complications; although, it has also been shown to perform quite similarly in simulating trial outcomes [33] . The main contribution was an international comparison including six countries, which allowed determining the possible discrepancies in cost-effectiveness ratios.
Sitagliptin was beneficial as compared with sulfonylureas by the reduction of hypoglycemia episodes and avoidance of weight gain [4] . The ICER of sitagliptin versus the sulfonylureas varied from 5949 €/QALY in Portugal to 20,350 €/QALY in Austria [12] . Discrepancies in incremental effectiveness may contribute to these differences, from 0.037 QALYs in Austria to 0.056 QALYs in Portugal. The Portuguese population considered in this study had a larger body mass index (BMI) (34.77 kg/m 2 , for men) as compared with Austria (26.12 kg/m 2 , for men), possibly explaining the higher benefits of sitagliptin. There were also discrepancies in incremental costs, from 331 € in Portugal to 760 € in Austria. This was partly explained by the difference in price between sitagliptin and sulfonylureas, from 1.55 € in Portugal to 1.78 € in Austria. The higher costs of macro-and micro-vascular complications in Austria might have been compensated for by their lower probability of occurrence, given the lower BMI and zeropercent smoking rate in the sample. Note that a more recent study for Portugal, which replicated the same analysis, found a value of 11,198 €/QALY [13] . The higher ICER, compared with the value obtained for Portugal in the international comparison, is explained by the higher treatment costs.
Second, we analysed the cost-effectiveness of saxagliptin compared with sulfonylureas [14] [15] [16] [17] [18] , mainly as add-ons to metformin, in patients not controlled with metformin monotherapy. The studies used a stochastic simulation model especially designed to evaluate the impact of new therapies in people with T2DM (Cardiff Diabetes model) [34] [35] [36] . Although possibly less comprehensive than the IMS core model, this model performed comparably when compared with trials outcomes [34] . It provided a reasonable prediction of treatment effects but tended to underestimate or overestimate the risks of complications.
The major advantages of saxagliptin as compared with sulfonylurea were the reduction in the number of hypoglycemia episodes, which influences the quality of life, and the avoidance of weight increases [16] . The incremental effectiveness was rather similar across studies, with values of 0.10 QALYs in Sweden [16] , 0.12 in Germany [15] , and 0.14 in Portugal [18] . A higher value was observed for Argentina [14] , of 0.22 QALYs, possibly due to the older base population (64 years old, compared with 60 or younger in the other studies), and longer duration of diabetes (more than 10 years, compared with less than 6 in other studies).
The US study was a clear outlier, indicating an incremental effectiveness of 2.65 QALYs [17] . This very favourable effect of saxagliptin in the US study was related to the much lower QALYs for the patients treated with sulfonylureas, of 8.37, compared with values above 9.32 in the other studies. We interpret this discrepancy through the base characteristics of the population considered in the US study, which had a much higher average BMI (34.01 kg/m 2 versus lower than 31.20 kg/m 2 in the other studies, from our own calculations), explaining the largely unfavourable outcomes for the patients treated with sulfonylureas.
The incremental costs varied little across studies, from 761 € in Portugal [18] to 2,447 € in the US [17] . The ICER values ranged from 5,307 €/QALY to 13,931 €/QALY. The US case was an outlier in terms of ICER, as expected from the incremental effectiveness outcome, with a much lower value of 924 €/QALY.
Third, we observed that saxagliptin in combination with metformin had an ICER of 6790 €/QALY when compared with insulin; the ICER was 6100 €/QALY in combination with sulfonylurea [19] . The benefits were driven by the lower risk of hypoglycaemic events and the neutral effect on weight [19] . A quite similar ratio was obtained in Sweden, by Kiadaliri et al. [31] , which compared the DPP-4 inhibitors to insulin, finding an ICER of 3824 €/QALY.
Fourth, a single study compared saxagliptin with pioglitazone, in combination with metformin, and found that saxagliptin was dominant (greater effectiveness and lower cost) [20] . The price of saxagliptin is lower, while the benefits are greater, namely the higher glycaemic control.
Fifth, one single study was obtained for vildagliptin, compared with sulfonylureas [21] , all as add-ons to metformin, in patients not controlled with metformin monotherapy. The vildagliptin versus sulfonylurea model was constructed as a patient-level simulation model, utilizing the risk equations from the UKPDS outcomes model to predict microvascular and macrovascular complications and mortality (both disease-specific and all-cause) over a 40-year horizon [21] . Vildagliptin had a similar clinical benefit in comparison to sulfonylurea; namely it avoids the weight gain and reduces the risk of hypoglycemia [4] . Vildagliptin had an ICER of 9072 €/QALY compared with sulfonylureas, using the Portuguese National Health Service perspective.
Sixth, we examined the comparison between liraglutide and sitagliptin [22] [23] [24] [25] [26] [27] [28] [29] . The studies that compared liraglutide with sitagliptin, all as add-ons to metformin as secondline therapy, used the CORE diabetes model (IMS Health, The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic… 961
Basel, Switzerland). This model, widely used and validated, allows estimating the long-term health outcomes and economic consequences of diabetes, with the possibility also of measuring the impact of different treatments and patient management strategies [37] . It has become a reference in the field because it integrates a comprehensive set of complications, and accounts for multiple risk factors. Also, it combines a Markov structure with Monte Carlo simulations, which allows measuring the joint progression and interactions between complications, and the effect of event history. On the one hand, most of the studies were based on the same measurements of benefits, so that the incremental effectiveness was quite similar across studies. In particular, six out of eight studies were based on the same random clinical trial, by Pratley et al. [38] . According to Li et al. [22] , using effectiveness measures (i.e., from the real world), the benefits of liraglutide compared with sitagliptin are driven by improved HbA1c and by greater weight loss. Noticeably, all studies considered a population with a BMI higher than 30 kg/m 2 , so that the results must be interpreted as relevant for this specific sub-population. For the 1.2-mg dosage, the incremental effectiveness varied from 0.17 QALYs in Spain [27] to 0.20 in the US [29] ; for the 1.8-mg dosage, it varied from 0.31 QALYs in the UK [28] to 0.40 in Spain [26] .
On the other hand, the variations in incremental costs ranged between 2297 € in Spain [27] to 6110 € in Sweden [23] , for the 1.2-mg dosage. This resulted in ICERs of relatively similar values, from 13,266 €/QALY in Spain [27] to 22,724 €/QALY in the US [29] . For the 1.8-mg dosage, the values varied between 4000 € and 5000 € except for the US, where the incremental cost rose to 11,689 € [29] . This resulted in a much higher ICER in the US, of 32,869 €/QALY, compared with values below 15,000 €/QALY in other countries. This much higher incremental cost in the US, driving a much less favourable ICER, was mainly due to the discrepancy in treatment costs: in the US, the liraglutide treatment is twice as costly as the sitagliptin, while it is only 16 % higher in the UK (according to our own calculation) [28] . Note also that the US study adopted a time-horizon of 3 years only, possibly omitting potential long-term consequences of treatments, so that its findings are hardly comparable.
Seventh, insulin glargine was compared with sitagliptin as add-ons to metformin [30] , and was found to be dominant in Canadian settings. The model also used the IMS CORE diabetes model [37] . The model considered a timehorizon of 50 years, and was populated with data from the EASIE trial. The insulin glargine increased the number of hypoglycaemic episodes but achieved a greater reduction of HbA1c [30] . This resulted in a slight benefit, of 0.08 QALYs, obtained with a lower treatment cost, due to the lower costs of treatment and disease complications.
Eighth, the GLP-1 receptor agonists (exenatide and liraglutide) were compared with DPP-4 inhibitors as addons to metformin [31] . The authors used the IHECM-T2DM model, which was previously described and used to compare cost-effectiveness of one of the GLP-1 receptor agonists, liraglutide, versus sulfonylureas or sitagliptin in Sweden. This model includes yearly cycles and a timehorizon of up to 40 years. The macrovascular health states were based on the UKPDS models and on the Swedish national diabetes register equations [31] . The authors calculated a gain of 0.10 QALYs for GLP-1 receptor agonists, driven by the better control of glycemia and weight reductions. These benefits were achieved at an additional cost of 3698 €, resulting in an ICER of 37,463 €/QALY in Swedish settings.
Discussion
The DPP-4 inhibitors represent substantial benefits in the treatment of type-2 diabetes, but also a considerable challenge for health systems due to their high prices. There is thus a clear need to perform economic evaluations of these new therapies, to guide policy-makers in their decisions regarding co-payments, therapeutic guidelines, and reimbursement strategies.
Key findings
This systematic review of the literature shows first and foremost that the evidence on cost-effectiveness is still recent and scarce, but is based on studies of overall high quality. In particular, most of the studies were based on published clinical trials for the measurement of consequences, and on official unit prices and country-specific resource use for costs. The studies used different but validated models, with comparable characteristics and predictive power, which all considered long time-horizons and the various health consequences of diabetes.
According to our findings, the DPP-4 inhibitors appear as highly cost-effective in most of the cases, following the WHO criterion and using the Organisation for Economic Co-operation and Development (OECD) GDP per capita values for 2015 as Ref. [39] . All as addons to metformin, sitagliptin, saxagliptin, and vildagliptin had an ICER below 25,000 €/QALY when compared with sulfonylureas. When compared with NPH insulin, saxagliptin as add-on to metformin or sulfonylurea had an ICER below 10,000 €/QALY. Saxagliptin was dominant as compared with pioglitazone. These ratios were driven mainly by the reduction in the risk of hypoglycaemic events, and in the avoidance of weight gain.
Some variations across studies are worth mentioning. In particular, the ratios for sitagliptin and saxagliptin varied due to differences in baseline patient characteristics. The findings were more favourable, from an economic viewpoint, for the sub-group of patients with a higher BMI, who were older, and who had been suffering from long-standing diabetes. By contrast, in most cases there was little variation in incremental costs, so that these may not be considered as a major cause of ICER discrepancies.
Some studies evaluated more recent alternative therapies, namely the GLP-1 receptor agonists and insulin glargine. When compared with sitagliptin, liraglutide was highly cost-effective. Note that this result was obtained only for populations with an average BMI higher than 30 kg/m 2 ; the favourable results are mainly explained by the reduction in weight and better control of glycemia achieved by GLP-1 receptor agonists. The insulin glargine was demonstrated to be dominant when compared with sitagliptin, related to the higher decrease in HbA1c and the lower price of the drug.
Comparison with earlier literature
To the best of our knowledge, two earlier systematic reviews of economic evaluations of DPP-4 inhibitors have been performed, in 2010 [40] and 2015 [41] . Given the rapid introduction of new drugs, we considered only the last review as a relevant comparison for our study. The major difference is that we retrieved 20 studies, in comparison to 11 in the review by Geng et al. [41] , mainly due to the analysis of recently introduced GLP-1 receptor agonists.
Our findings were quite similar in regard to the comparison between DPP-4 inhibitors and sulfonylureas, both as add-ons to metformin, concluding that DPP-4 inhibitors are cost-effective in patients who do not achieve glycaemic targets with metformin. In comparison with thiazolidinediones, Geng et al. [41] found five papers that came to uncertain conclusions; in comparison, we only retrieved one single paper, because we did not consider comparisons with rosiglitazone, whose marketing authorization was suspended in Europe due to safety issues.
Limitations
This study has some limitations. First, a relatively small number of articles met the inclusion criteria for some comparisons, namely DPP-4 inhibitors versus thiazolidinediones (one single study), and DPP-4 inhibitors versus insulin (two studies). Obviously, this represents too little evidence to draw robust conclusions. Regarding thiazolidinediones, this does not represent a major problem given their low utilization in current practice [42] . For insulin, this is a more serious issue given the high number of users; in this sense, the lack of economic evaluations was quite surprising, and further research is needed to elaborate solid recommendations.
Second, as mentioned by Waugh et al. [40] , most studies were funded by manufacturers. Even though these studies were often carried out by independent consultants, this can lead to a publication bias, the unfavourable findings not being diffused [43] . More generally, these limitations highlight the urgent need for independent economic evaluations of DPP-4 inhibitors and other new treatments, e.g. by State agencies.
Third, the health consequences were measured in most studies using the same randomized control trials. For example, the D1680C00001 trial was used in the studies for Argentina, Germany, Portugal Sweden, and the US. On the one hand, observational studies should be carried out to confirm the favourable outcomes in real-world practice, which may produce different outcomes according to population characteristics, patients' attitudes, and physicians' practices. There is evidence, for example, of the use in actual practice of DPP-4 inhibitors as single compounds or in combination with sulfonylureas [44] . On the other hand, the reliance on a few trials is problematic because it may not encompass the possible different outcomes according to populations' characteristics. In particular, the ADA/ EASD guidelines mention that the choice of the secondlines should be based on ''a variety of patient and disease specific factors'' (p. 145) [4] . The lack of variety in the populations under scrutiny limits the contributions of the studies for drug evaluation across sub-populations.
Finally, relevant databases such as Econlit, CINAHL, EMBASE, and Psychoinfo were not included in the search strategy, because they were not accessible for free. Note, however, that we have used the most commonly used databases in systematic reviews of economic evaluations. Future cost-effectiveness studies should be repeated during the lifecycle of medicines under real-world utilization and incorporate budget impact analysis.
Conclusions
According to WHO thresholds, there is consistent evidence about the cost-effectiveness of DDP-4 inhibitors as secondline, as add-ons to metformin, in comparison with sulfonylureas. More recent therapies, namely the GLP-1 receptor agonists, were, however, demonstrated to be highly cost-effective in comparison to DPP-4 amongst populations with an average BMI higher than 30 kg/m 2 . Also, insulin glargine was demonstrated to be dominant when compared with DPP-4 inhibitors.
These results were, however, obtained on the basis of a limited number of studies, relying on the same few clinical trials, and financed by manufacturers, raising the issue of a possible publication bias. Further independent research is needed, with more experimental but also observational studies, to confirm these findings and incorporate them into therapeutic guidelines.
